CRO Oz-UK has announced that it is installing a new manufacturing line for metered dose inhalers that use LGWP propellants and expects the new line to be in operation by July 2024. According to the company, the line will be able to handle both HFO-1234ze and HFA-152a solution and suspension formulations, with batch sizes of 2.5 to 10 kg.
In addition to a recent announcement of an Oz-Uk partnership with CDMO Recipharm on development and manufacturing of LGWP MDIs, the company also announced in September 2022 that it was working with H&T Presspart on development services for MDIs using LGWP propellants.
Oz-UK Director David Lewis commented, “Development of inhalation products is limited by the difficulties of R&D in a pressurized environment and the propellant propulsion challenges of aerosol science. Our years of experience in this market mean that Oz-UK is uniquely positioned to support pharma at speed, with the facilities needed to undertake the R&D, formulation, and pilot testing of new pMDIs. We are already working on technical transfer and intellectual property transfer for a number of global businesses who have carried out this work with us, including Recipharm who also announced a collaboration with Oz-UK for its initiative to accelerate the development and manufacture of ‘green’ pMDIs. The introduction of our new low-GWP line will enable more companies to undertake these projects more quickly as the deadline for F-gas phase-down approaches.”
Read the Oz-UK press release.
